John Wirthlin is a results-driven executive with an 18-year record of successfully growing innovative healthcare technology companies. Prior to Metrodora, Mr. Wirthlin served as the CEO of Lumea, where he launched the first-of-its-kind digital pathology SaaS software platform, successfully scaling the technology to capture 10% of the urology market with over 400,000 end users. In addition, Mr. Wirthlin led strategic collaborations with Google, Verily, Tempus and others to develop and deploy cutting edge AI solutions for cancer diagnostics, genetic testing and precision medicine on Lumea’s software platform. Prior to Lumea, Mr. Wirthlin was the founder and CEO of AlloCure. AlloCure was a biotechnology company developing therapeutics to treat kidney disease. During his time at AlloCure, he raised over $50MM from national and international venture capital firms and successfully progressed its drug development program (AC607) through phase II clinical trials. Mr. Wirthlin previously worked for Echelon Biosciences Inc. where he served as Director of Business Development and Director of Operations. Echelon was successfully acquired by Aeterna Zentaris in 2004. Mr. Wirthlin is a strategic leader with a comprehensive skill set and a proven ability to drive growth and innovation in complex business environments.